Prospective One-Year Outcomes of Preserflo MicroShunt Implantation in Glaucoma Following Keratoplasty

PRÉCIS: This study evaluates the efficacy and safety of Preserflo MicroShunt implantation in secondary glaucoma following corneal transplantation over a consecutive 1-year follow-up period, demonstrating high success, significant IOP reduction, and no observed graft decompensation. PURPOSE: This study aims to assess the efficacy and safety of Preserflo MicroShunt (PMS) implantation in patients with secondary glaucoma following keratoplasty over a 1-year follow-up. METHODS: In this prospective, single-center study, 19 patients (19 eyes) diagnosed with secondary glaucoma following corneal graft surgery were included for PMS implantation. The study cohort comprised 17 eyes after penetrating keratoplasty and 2 after deep anterior lamellar keratoplasty. The primary outcome measures were intraocular pressure (IOP) reduction, success rates, glaucoma medication use, endothelial cell density (ECD), and visual acuity after the procedure. An IOP reduction of 20% compared with the baseline value without reintervention was considered a successful treatment. Complete success was defined as discontinuation of antiglaucoma medications. Secondary outcome measures included intraoperative and postoperative complications. Measurements were performed preoperatively and at 1 day, 1 week, 1, 3, 6, and 12 months postoperatively. RESULTS: The reduction in IOP was statistically significant at follow-up visits compared with baseline, with a mean decrease of 57.8% at the final follow-up. Similarly, the number of antiglaucoma medications was significantly reduced at follow-up visits relative to baseline. The qualified success rate was 84.2% and the complete success rate was 63.2%. There were no statistically significant differences in visual acuity or endothelial cell density (ECD) compared with preoperative values. CONCLUSION: Preserflo MicroShunt implantation appears to be an effective and well-tolerated method of reducing intraocular pressure in patients with secondary glaucoma following keratoplasty. Long-term follow-up in a larger patient cohort is needed to confirm these results.